Vor Biopharma grants 56,345 stock options

Vor Biopharma Inc. reported that director Alexander Cumbo received a grant of stock options on Common Stock as part of his compensation.

Rhea-AI Filing Summary

Vor Biopharma Inc. reported that director Alexander Cumbo received a grant of stock options on Common Stock as part of his compensation. The award covers 56,345 options with an exercise price of $14.09 per share, all held directly.

These options expire on June 10, 2036 and relate to 56,345 underlying shares of Common Stock. According to the vesting terms, one thirty-sixth of the options will vest and become exercisable on July 11, 2026 and each month thereafter, conditioned on Mr. Cumbo’s continued service through each vesting date.

Insider Trade Summary

Grant/Award: 56,345 shares

Grant/Award 1 txn

Insider Cumbo Alexander

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	56,345	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 56,345 contracts (Direct)

Footnotes (1)

1. F1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

Option grant size: 56,345 options Exercise price: $14.09 per share Underlying shares: 56,345 shares +3 more

6 metrics

Option grant size 56,345 options Grant of stock options on Common Stock

Exercise price $14.09 per share Exercise price of granted stock options

Underlying shares 56,345 shares Common Stock underlying the options

Post-grant derivative holdings 56,345 options Total options held following this transaction

Option expiration June 10, 2036 Expiration date of the stock options

Vesting commencement July 11, 2026 First vesting date for one thirty-sixth of options

Key Terms

Stock option (right to buy), exercise price, expiration date, Common Stock, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 14.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alexander Cumbo receive in this Vor Biopharma (VOR) Form 4 filing?

Alexander Cumbo received a grant of 56,345 stock options on Vor Biopharma Common Stock. The options are part of his compensation and give him the right to buy shares at a fixed exercise price of $14.09 per share until expiration.

What is the exercise price of the new Vor Biopharma (VOR) stock options?

The granted stock options have an exercise price of $14.09 per share. This means Cumbo can buy Vor Biopharma Common Stock at $14.09 once options vest, regardless of future market price, until the options expire on June 10, 2036.

How many Vor Biopharma (VOR) shares are covered by Alexander Cumbo’s options?

The option grant covers 56,345 underlying shares of Vor Biopharma Common Stock. Each option corresponds to one share, so if fully vested and exercised, Cumbo could purchase up to 56,345 shares at the fixed $14.09 exercise price.

When do Alexander Cumbo’s Vor Biopharma (VOR) options start vesting?

Vesting begins on July 11, 2026, when one thirty-sixth of the options vest. An additional one thirty-sixth vests each month thereafter, as long as Cumbo continues to serve, creating a three-year monthly vesting schedule from that initial vesting date.

What is the expiration date of the Vor Biopharma (VOR) stock options granted to Cumbo?

The stock options expire on June 10, 2036. After that date, any unexercised options become worthless. Until expiration, vested options allow Cumbo to purchase Vor Biopharma Common Stock at the fixed $14.09 exercise price set in the grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 08:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cumbo Alexander

(Last) (First) (Middle)

500 BOYLSTON STREET, SUITE 1350

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$14.09	06/11/2026		A		56,345		(1)	06/10/2036	Common Stock	56,345	$0	56,345	D

Explanation of Responses:

1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Adi Osovsky, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)